The significance of specific diagnosis in the treatment of epilepsies

EB Posner,C. Panayiotopoulos

DOI: https://doi.org/10.1111/j.1469-8749.2008.03120.x

2008-11-01

Developmental Medicine & Child Neurology

Abstract:The report by Verrotti et al. in this issue illustrates the advances made towards a specific diagnosis and treatment of the epilepsies. Its strength is that the population study is properly defined according to formalized International LeagueAgainstEpilepsy definitions. In epilepsies, success of treatment depends on seizure diagnosis and long-term management requires a syndromic diagnosis. Antiepileptic drugs (AEDs) beneficial for focal seizures may be contraindicated in generalized seizures and indeed their effect may be different in absence, myoclonic, and generalized tonic–clonic seizures (GTCS). Typical absence seizures (TAS) are brief generalized seizures that are fundamentally different from any other type of seizures, and therefore unique in terms of pharmacological treatment. They usually occur in the context of idiopathic generalized epilepsies (IGE) either alone or in combination with myoclonic jerks and GTCS. TAS are the defining seizures of childhood absence epilepsy (CAE) and juvenile absence epilepsy (JAE). They are of less prominence in juvenile myoclonic epilepsy (JME). CAE manifests with numerous and severe TAS, usually limited to childhood. JAE typically starts in adolescence with severe TAS that continue in adulthood together with GTCS. Myoclonic jerks on awakening and GTCS are the main seizures of JME while absences are usually mild. AEDs are mainly tested and licensed for focal epilepsies but many of them are inappropriate for the treatment of IGE and TAS. Vigabatrin and tiagabine are pro-absence drugs that induce absence seizures. Carbamazepine, phenytoin, phenobarbital, gabapentin, and pregabalin are either ineffective or exaggerate TAS. Valproic acid, ethosuximide, and lamotrigine, alone or in combination, are currently the first-line therapy for TAS. Valproic acid controls absences in 75% of patients and also GTCS (70%) and myoclonic jerks (75%); however, it has undesirable adverse effects particularly for females. Lamotrigine controls absences and GTCS in 50 to 60% of patients, but may worsen myoclonic jerks; idiosyncratic adverse reactions are common. Ethosuximide controls 70% of absences, but it is unsuitable for monotherapy if myoclonic jerks and GTCS coexist. Low dosages of lamotrigine added to valproic acid may have a dramatic beneficial effect. Clonazepam (particularly in TAS with myoclonic components) or lessoftenacetazolamidemay beuseful adjunctivedrugs. Levetiracetam is a broad spectrum AED licensed for monoand adjunctive therapy in focal seizures and adjunctive treatment in primarily GTCS of IGE and myoclonic seizures of JME, thus combining therapeutic properties of carbamazepine and valproic acid. In paediatrics some of these indications refer to children from age 4 years and older. It has a relatively good safety profile and does not needslowtitration. Levetiracetam has been in clinical use for over 8 years but its effect on TAS has been largely unknown. The report by Verrotti et al. is the first published comprehensive study of the efficacy of levetiracetam in children with CAE and JAE. Half of newly diagnosed patients with CAE and JAE were seizure-free and most of the remaining patients significantly improved at 1 year on levetiracetam monotherapy without significant adverse effects. Of interest is that this beneficial outcome on TAS control was mainly seen in CAE rather than JAE. These are promising findings but the study was small, unblinded, and TAS were assessed on mainly historical counts by parents.Thus, the results need confirmationby double blind randomized controlled trials. In the USA, the primary aim of an ongoing large-scale study (supported with a $14 million grant from the National Institute of Neurological Disorders and Stroke) is to determine the best initial treatment for CAE but only ethosuximide, valproic acid, and lamotrigine are considered. By contrast, for levetiracetam only a small scale pilot trial was started but this has been abandoned due to ‘lack of patient participation’. How does this all translate into paediatric clinical practice? CAE is usually easily diagnosed on the basis of numerous and severe TAS that can be reproduced in the clinic by asking the child to overbreathe. The EEG is diagnostic. Problems arise when first-line AED monotherapy fails. It is not long ago that nearly half of these children were inappropriately treated with carbamazepine and even vigabatrin. Another problem is when TAS occur together with myoclonic jerks and GTCS which commonly indicates epileptic syndromes other than CAE, i.e. JAE and JME. JAE and JME continue into adult life and their treatment requires AEDs that are effective in the triad of generalized seizures (TAS, myoclonic jerks, and GTCS). This is where levetiracetam may successfully compete with valproic acid (JMEandJAE)and lamotrigine (JAE).Adverseeffectsdifferbetween these AED and should be considered in accordance with the individual’s needs. AED contraindicated in TAS and related epileptic syndromes should be clearly noted in the national formularies. An AED is contraindicated not only when it exaggerates seizures but also when it is ineffective in controlling the seizures that it is supposed to treat. It may cause unnecessary adverse reactions and deprives thepatientof the therapeuticeffect that couldbeprovided by anotherAED.